X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

CEVA Logistics opens Singapore cold station as part of global healthcare logistics solution

Content Team by Content Team
13th September 2021
in Packaging & Logistic, Press Statements
CEVA Logistics opens Singapore cold station as part of global healthcare logistics solution

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

CEVA Logistics opened its temperature-controlled airfreight station today adjacent to Singapore’s Changi International Airport, positioning Singapore as a strategic healthcare logistics hub for the Asia Pacific region.

CEVA’s latest cold station lies within the Free Trade Zone of the Airport Logistics Park of Singapore, facilitating seamless regional distribution in the Association of Southeast Asian Nations (ASEAN) region and providing in-transit storage, value-add services and quick turnaround times for connecting to global markets.

Airfreight stations part of expanding healthcare logistics offering

CEVA’s growing network of cold stations is in direct service of its Temperature Sensitive Solution, a pharmaceutical logistics offering ensuring that temperature-sensitive shipments across ambient and chilled conditions are maintained in their optimal environments throughout shipment.

The CEVA Logistics temperature-controlled solution required capital investment in specialized airfreight facilities around the world, and with the support of its parent company, the CMA CGM Group, a world leader in shipping and logistics, CEVA remains committed to operating a network of more than 40 such airfreight stations by the end of 2021. Additional stations in Atlanta, Chicago, Frankfurt, Madrid, Budapest and Mumbai are scheduled to open in the coming months. In all, the stations will allow CEVA to not only service major healthcare gateways in regional markets, like Asia Pacific, but also to supply more than 1,450 healthcare trade lanes globally.

To meet the demands of healthcare and pharmaceutical customers, the new station is composed of two distinct areas dedicated to temperature management of shipments within the ranges of 15 to 25 degrees Celsius and 2 to 8 degrees Celsius. CEVA will continue to focus on the spectrum of products requiring a range of 2 to 8 degrees Celsius, including certain COVID-19 vaccines, although the company provides solutions for other products, including vaccines requiring lower temperatures throughout transport.

Additional solutions such as Controlant, an automated control tower workflow tool, and Validaide, a risk assessment tool on lane validations, will also be available for customers to ensure reliability and compliance. The Singapore location’s proximity to local seaports, combined with reefer container options, also allows customers to access more environmentally friendly ocean freight transportation.

CEVA FORPATIENTS offers a wide range of healthcare and pharmaceutical logistics

The CEVA FORPATIENTS suite of healthcare logistics encompasses temperature sensitive solutions, pharma and biopharma, medical devices, consumer health, hospital and home care, as well as diagnostic and laboratory services. In healthcare and pharmaceutical markets, CEVA serves more than 500 healthcare and life science companies globally, more than 50 healthcare contract logistics operations worldwide and 20 of the top 30 medical device supply chains.

Says Elaine Low, managing director for Southeast Asia and Pacific, CEVA Logistics: “As CEVA’s first airfreight cold chain facility in Singapore, this is a timely investment for healthcare logistics. This air hub is now capable of supporting the regional distribution of vaccines and other pharmaceutical supplies that are critically needed in Southeast Asia at the moment. In addition, our healthcare customers will benefit from the range of value-added services, such as dry ice, relabelling and cross-stocking within the free trade zone.”

Says Niels van Namen, executive vice president of global healthcare, CEVA Logistics: “Our FORPATIENTS commitment is driving our investment in healthcare logistics. These airfreight cold chain stations are just one more example of how we put the patient first, even in the supply chain. We have the expertise and now another facility to continue supporting customers who require stringent temperature management within their global supply chains to ensure the integrity of their patients’ products.”

About CEVA Logistics

CEVA Logistics, a world leader in third-party logistics, provides and operates transportation and supply-chain solutions for large- or medium-size national and global companies. CEVA Logistics offers a broad range of services in both Contract Logistics and Freight Management thanks to its approximately 78,000 employees and 1,000 facilities in more than 160 countries. CEVA Logistics’ experienced specialists focus on seamlessly designing end-to-end customized solutions to meet the complex and rapidly evolving supply chain needs, whatever the business sector. CEVA Logistics is part of the CMA CGM Group, a world leader in shipping and logistics.

Previous Post

Easyfairs partners with MIND Exhibitions to launch Connect in Pharma

Next Post

Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
Future Trends Shaping
Packaging & Logistic

Future Trends Shaping Pharma Supply Chain and Logistics

30th July 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Next Post
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

Resilience to Manufacture mRNA for Moderna's COVID-19 Vaccine

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In